DVAX - ダイナバックス・テクノロジ―ズ (Dynavax Technologies Corporation) ダイナバックス・テクノロジ―ズ

 DVAXのチャート


 DVAXの企業情報

symbol DVAx
会社名 Dynavax Technologies Corp (ダイナバックス・テクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ダイナバクス・テクノロジーズ(Dynavax Technologies Corporation)は臨床段階の免疫療法会社である。同社はトール様受容体(TLR)刺激を通じて身体の本能と適応免疫応答を活用することに集中する。同社の製品候補は複数の癌適応症、B型肝炎の予防ワクチン、および喘息疾患修正療法として開発される。同社の製品はHEPLISAV-B、AZD1419、SD-101、DV281、DV230FとDV1001を含む。HEPLISAV-Bは治験成人のB型肝炎ワクチンである。AZD1419は喘息の治療として開発される。SD-101は癌に対する免疫応答を誘発するように設計される治験用TLR9アゴニストである。DV281は原発性肺腫瘍および肺転移への集中送達のためのTLR9アゴニストである。DV230Fは肝腫瘍の治療に適応する。DV1001は複数悪性腫瘍のTLR7、8アゴニストを標的とする。DV230FとDV1001は開発の前臨床段階である。   ダイナバックス・テクノロジ―ズは米国の臨床検査段階のバイオ医薬品会社。感染症、炎症性疾、自己免疫疾患治療薬の研究、開発に従事。候補製剤にはB型肝炎ワクチン「ヘプリサブ」、自己免疫疾患治療用「DV1179」、喘息治療用「AZD1419」、癌免疫療法「SD-101」などがある。   
本社所在地 2929 Seventh Street Suite 100 Berkeley CA 94710-2753 USA
代表者氏名 Arnold L. Oronsky アーノルドエルオロスキー
代表者役職名 Independent Chairman of the Board
電話番号 +1 510-848-5100
設立年月日 35278
市場名 NASDAQ Small Cap
ipoyear 2004年
従業員数 170人
url www.dynavax.com
nasdaq_url https://www.nasdaq.com/symbol/dvax
adr_tso
EBITDA EBITDA(百万ドル) -115.44000
終値(lastsale) 11.07
時価総額(marketcap) 693154537.02
時価総額 時価総額(百万ドル) 700.66840
売上高 売上高(百万ドル) 1.49300
企業価値(EV) 企業価値(EV)(百万ドル) 584.39640
当期純利益 当期純利益(百万ドル) -127.95100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Dynavax Technologies Corporation revenues increased from $253K to $1.4M. Net loss increased 72% to $78.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing v increase from $2.3M to $17.5M (expense).

 DVAXのテクニカル分析


 DVAXのニュース

   Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates  2020/12/04 08:00:00 Business Wire
CHENGDU, China.--(BUSINESS WIRE)--Clover Biopharmaceuticals, a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines and therapeutics for the world’s most debilitating diseases, today announced positive clinical data from its Phase 1 trial demonstrating that its protein-based COVID-19 S-Trimer vaccine candidates in combination with adjuvants from either GSK (London Stock Exchange: GSK) or Dynavax (Nasdaq: DVAX) induces strong immune responses,
   Biological E to start phase-III trials by January, license vaccine by summer  2020/11/24 05:02:08 Economic Times India
Hyderabad: Hyderabad-based Biological E, which recently obtained the drug regulator’s nod to start phase I and II clinical trials of its Covid-19 vaccine candidate, hopes to enter into phase-III clinical trials by January-end and license the vaccine by summer.Disclosing this in Hyderabad on Monday, managing director Mahima Datla said the company is currently evaluating four different formulations depending on different antigen strengths in the phase I-II combined studies.Without having to wait to do a dose finding study, Biological E, with preliminary immunogenicity data from 400 people by February, will enter into phase-III trials where about 30,000 people will participate.“We just began our phase I-II study and in our case we combined the phase I and II because we wanted to directly evaluate four different formulations depending on different antigen strengths,” said Mahima. “This data is expected to be available by the end of January.”The Drugs Controller General of India had last week allowed Biological E to start phase I-II trials of Covid-19 vaccine candidate which includes an antigen that was in-licensed from BCM Ventures, an integrated commercialisation team of Baylor College of Medicine in Houston.Biological E had also in-licensed an advanced adjuvant from the US-based vaccine focused pharmaceutical firm Dynavax Technologies Corporation. “The good news is from then (after phase I-II trials by January-end) we will directly go to a phase III study and we won’t need to do a dose finding study again.
   India's COVID-19 Vaccine COVAXIN's Final Trials Could End In 2 Months: Harsh Vardhan  2020/11/23 03:19:42 HuffPost India
NEW DELHI — India ’s health minister said on Sunday a locally-developed COVID-19 vaccine candidate could complete its final trials in a month or two, raising hopes for a rapid roll-out in a country with the world’s second highest number of infections. The state-run India n Council of Medical Research (ICMR) and privately-held Bharat Biotech this month started third-stage trials of COVAXIN, in a process that would involve 26,000 volunteers. It is the most advanced India n experimental vaccine. “We are in the process of developing our indigenous vaccines, in the process of completing our third-phase trials in the next one or two months,” Harsh Vardhan told a web conference on the pandemic. He reiterated the government’s plan was to immunise 200 million to 250 million India ns by July. Related… Will Covid-19 Vaccines Achieve Herd Immunity? Experts Explain Why Moderna's Vaccine Announcement Has Experts So Enthusiastic Oxford Covid Vaccine 'Produces Strong Immune Response In Older Adults' An ICMR scientist told Reuters earlier this month the vaccine could be launched in February or March, although Bharat Biotech separately told Reuters on Friday that results of the late-stage trials were expected only between March and April.
   Biological E. Limited Starts Phase I/II Clinical Trial of its COVID-19 Vaccine Candidate  2020/11/16 11:00:00 PR Newswire
HYDERABAD, India and HOUSTON and EMERYVILLE, Calif., Nov. 16, 2020 /PRNewswire/ -- Biological E. Limited (BE), a Hyderabad-based vaccines and pharmaceutical company, Dynavax Technologies Corporation (NASDAQ: DVAX), a US-based vaccine focused biopharmaceutical company, and Baylor College…
   Dynavax Announces Third Quarter 2020 Financial Results  2020/11/05 21:01:00 PR Newswire
EMERYVILLE, Calif., Nov. 5, 2020 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the third quarter of 2020. "The current global pandemic highlights…
   Thinking about buying stock in Cassava Sciences, Mersana Therapeutics, Sorrento Therapeutics, Dynavax Technologies, or Co-Diagnostics?  2020/09/14 13:31:00 PR Newswire
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SAVA, MRSN, SRNE, DVAX, and CODX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding…
   Worldwide Cancer Vaccines Industry to 2027 - Featuring Advaxis, Amgen & Dynavax Technologies Among Others  2020/09/08 15:45:00 PR Newswire
DUBLIN, Sept. 8, 2020 /PRNewswire/ -- The "Cancer Vaccines Market by Technology, Type, Indication and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global cancer vaccines market was valued at $4,188…
   Gates Foundation awards $3.4 million for COVID-19 vaccine adjuvant  2020/08/19 04:01:00 Philanthropy News Digest
The grant will enable biopharmaceutical company Dynavax Technologies Corporation to increase production capacity for its CpG 1018 advanced adjuvant and ensure its availability for collaboration partners developing adjuvanted vaccines for SARS-CoV-2….
   Dynavax Technologies shares are trading higher after the company announced it will sell its SD-101 oncology program to TriSalus Life Sciences in a purchase agreement for up to $250 million in milestone payments plus royalties on future net sales.  2020/08/03 14:41:00 Benzinga
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …
   The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold  2020/07/21 11:58:40 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX ) AstraZeneca plc (NYSE: AZN ) ( announced positive Phase 1/2 readout for the coronavirus vaccine it is co-developing with the Oxford University) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) (reacted to positive late-stage readout for BXCK501 in treating schizophrenia and bipolar disorder) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Catalent Inc (NYSE: CTLT ) Cytosorbents Corp Inc (NASDAQ: CTSO ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Emergent Biosolutions Inc (NYSE: EBS ) Fortress Biotech (NASDAQ: FBIO ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Illumina, Inc.
   Gates Foundation awards $3.4 million for COVID-19 vaccine adjuvant  2020/08/19 04:01:00 Philanthropy News Digest
The grant will enable biopharmaceutical company Dynavax Technologies Corporation to increase production capacity for its CpG 1018 advanced adjuvant and ensure its availability for collaboration partners developing adjuvanted vaccines for SARS-CoV-2….
   Dynavax Technologies shares are trading higher after the company announced it will sell its SD-101 oncology program to TriSalus Life Sciences in a purchase agreement for up to $250 million in milestone payments plus royalties on future net sales.  2020/08/03 14:41:00 Benzinga
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …
   The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold  2020/07/21 11:58:40 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX ) AstraZeneca plc (NYSE: AZN ) ( announced positive Phase 1/2 readout for the coronavirus vaccine it is co-developing with the Oxford University) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) (reacted to positive late-stage readout for BXCK501 in treating schizophrenia and bipolar disorder) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Catalent Inc (NYSE: CTLT ) Cytosorbents Corp Inc (NASDAQ: CTSO ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Emergent Biosolutions Inc (NYSE: EBS ) Fortress Biotech (NASDAQ: FBIO ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Illumina, Inc.
   Thinking about trading options or stock in Dynavax Technologies, Vaxart Inc, Intuitive Surgical, Ford Motor, or Southwest Airlines?  2020/07/20 13:31:00 PR Newswire
NEW YORK, July 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DVAX, VXRT, ISRG, F, and LUV. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…
   5 Stock Gainers for Friday: VBI Vaccines, Moderna, Novavax  2020/07/17 20:23:27 The Street
Stocks trading higher Friday include VBI Vaccines, Moderna, Novavax, Dynavax Technologies, and Quidel.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ダイナバックス・テクノロジ―ズ DVAX Dynavax Technologies Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)